-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Edoxaban is an oral anticoagulant medication that is used to prevent blood clots from forming in the body.
It is primarily used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to reduce the risk of recurrent DVT and PE following initial treatment.
Edoxaban is also sometimes used to treat atrial fibrillation, a type of irregular heartbeat that can increase the risk of blood clots.
Edoxaban is a direct factor Xa inhibitor, which means it works by preventing the formation of thrombin, a clotting factor that is involved in blood clot formation.
By inhibiting thrombin formation, edoxaban helps to prevent thedevelopment of blood clots.
Edoxaban is taken orally, usually once daily, and is well-tolerated by most patients.
However, like all medications, it can cause side effects.
The most common side effects of edoxaban include minor bleeding, such as nosebleeds and bruising, and gastrointestinal symptoms, such as nausea and diarrhea.
More serious side effects, such as bleeding in the stomach or intestines, can occur, but are rare.
Edoxaban is available under the brand name LIXIANA and it's manufactured by Daiichi Sankyo Company.
It was approved by the FDA in 2015 and it's been widely used in the treatment of blood clot disorders.
In conclusion, Edoxaban is an effective oral anticoagulant medication that is used to prevent blood clots from forming in the body.
It is primarily used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to reduce the risk of recurrent DVT and PE